Please search for your last name

Michael J. Fox Foundation
Research Resources
Dr. Eberling received her PhD from the University of California at Berkeley and did her post-doctoral training in PET imaging at the Lawrence Berkeley National Laboratory. Prior to joining the Michael J. Fox Foundation in 2009, she did research using PET imaging to study Alzheimer’s disease and Parkinson’s disease, and was involved in the development and translation of gene therapy approaches for Parkinson’s disease. She now leads the imaging program at the Michael J. Fox Foundation and is responsible for efforts to develop novel PET tracers for Parkinson’s disease, including an alpha-synuclein PET tracer.
Curtin University
Curtin Medical School
Melissa is a final year PhD student currently enrolled at Curtin Medical School, Curtin University, Perth, Western Australia. In 2016 she graduated from a Bachelor of Science (Molecular Genetics and Biotechnology), receiving the Fisher Biotech award for the top graduating student, having been awarded Vice Chancellor’s Listing (top 1% of students) for ever semester of her studies. Subsequently she undertook a year-long Honours degree and graduated with First Class Honours in Biomedical Science (Hons). Melissa began her PhD project, investigating the role of presenilin homologues in β-amyloid metabolism in 2018 in the Verdile-Groth Neuroscience laboratory, receiving a Dementia Australia Research Foundation stipend scholarship to complete her studies. Melissa uses both molecular modelling and in-vitro experimental methods, having developed several novel cell lines to investigate the role of the presenilins in β-amyloid generation, clearance, and degradation. Throughout her PhD studies she has won several poster and oral presentation awards and been actively involved in the scientific community as a committee member of the Australian Society for Medical Research state branch. Melissa has also been instrumental in establishing multiple collaborations that have identified novel γ-secretase substrates associated with both melanoma and liver cancer.
Cogstate
Clinical Science
Dr. Chris Edgar has an extensive background in the application of clinical outcome assessments (COAs) in drug development and has worked in the pharmaceutical industry for over 20 years. He is the former scientific director of Cognitive Drug Research Ltd. developers of CDR System, one of the earliest computerized cognitive test systems to be widely employed in clinical trials. Dr. Edgar also has a background in COA management and rater training delivery with Bracket/UBC; and CNS/neuroscience clinical trial design and outcomes research with Roche, and as an independent consultant.
no photo
University of California, San Diego
Department of Family Medicine and Public Health
NeuroDex INC
R&D
I am the Chief Scientific Officer and founding scientist of NeuroDex, a startup biotechnology company committed to developing blood-based diagnostic tests for diverse neurological conditions. I am one of the pioneers in studying extracellular vesicles (EVs) in neurodegenerative diseases and their application as a diagnostic tool. At the National Institute of Aging (NIA) I have established and led extracellular vesicles research programs, which led to the discovery of the role of exosomes in the prion-like propagation of amyloid beta and paved the road to first studies utilizing blood EVs in neurodegenerative biomarker programs. Currently, as chief scientific officer at NeuroDex, a company I have founded, I am highly motivated to develop and commercialize EV-based assays. We developed unique and robust methods for EV isolation and quantification from blood fluids and applied it for biomarker discovery in Alzheimer’s, Parkinson's, and ALS.
Qatar Biomedical research Institute
Neurological Disorders Research Center
Dr. Omar El-Agnaf is considered a pioneer in the field of Parkinson’s and related neurodegenerative diseases. He received his Ph.D. in Biochemistry at the Queen’s University Belfast, UK in 1997, where he was appointed as a post-doctoral scientist at the School of Biology and Biochemistry until 1999. Following this, he undertook an additional two-year post-doctoral position at St. George’s Medical School, London. In 2001, he was awarded a Research Fellowship from the Parkinson’s Disease Society-UK to establish his research group at Lancaster University. Dr. El-Agnaf was appointed to the Biochemistry Department at the College of Medicine at UAE University after completing his Research Fellowship in 2004. In 2014, Dr. El-Agnaf joined HBKU, Qatar and was appointed Executive Director in 2018. His discoveries have significantly impacted the scientific research community, provided further insight into the molecular pathogenesis of Parkinson’s disease, and offered new opportunities for the development of novel diagnostic and therapeutic tools for the disease. He is currently a member of the editorial boards of several international journals. Publications in high-ranking scientific journals validate Dr. El-Agnaf's track record of excellent basic and translational research productivity. He has been granted 10 patents with 6 under consideration, and published 151 peer-reviewed articles.
Tel Aviv University
.
Professor Hagit Eldar-Finkelman Tel Aviv University Focuses on the molecular mechanisms underlying human disease and development of new innovative therapeutics addressing unmet needs in neurodegenerative disorders arena. We employ multidisciplinary research platforms from in vitro assays, computational analyses, and animal models to decipher signaling components that contribute to molecular pathogenesis, and to identify and design bioactive agents as future therapies. A major focus is given to GSK-3, a drug discovery target for treating neurodegeneration.
McGill University
Pharmacology & Therapeutics
Joshua is an up and coming Alzheimer's and dementia researcher with an interdisciplinary background in biology, neuroscience and pharmacology. His work focuses on elucidating amyloid and tau pathology from a preclinical and basic science perspective utilizing aged transgenic rodents. Possess skills in a wide range of techniques, including histology, biochemistry, rodent behaviour, electron microscopy, electrophysiology and rodent stereotaxic surgery. Approaching the end of his PhD, Joshua is a published author, has received multiple fellowships and possesses an aptitude for strong leadership.
Universität Heidelberg
IPMB, Functional Genomics
PhD student at Ulrike Müller's Lab at Heidelberg University, Department of Functional Genomics
University of Wisconsin-Madison
Medicine
Claire Erickson is a fifth year graduate student in the Neuroscience & Public Policy program at the University of Wisconsin-Madison. She works under the mentorship of Dr. Sterling Johnson within the Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center. Claire's research interests include modifiable factors in Alzheimer's disease trajectories, return of biomarker test results, and incorporating evidence into aging and long-term care policymaking.
no photo
Uppsala universitet
Department of Public Health and Caring Sciences
Ace Alzheimer Center Barcelona. Universitat Internacional de Catalunya
Memory Unit and Research Center
Dr. Ana Espinosa, is neuropsychologist and specialist in Dementias with a broad clinical and research experience in Spain. She holds a MSc in Neuropsychology from the Universitat Autonoma de Barcelona, and a MSc in Neurosciences from the Universitat de Barcelona (UB). Specialist in Clinical Neuropsychology and Assistant of Neuropsychology at the Diagnostic Unit of ACE Alzheimer Center Barcelona, since 2004. She obtained her PhD at the UB in the Doctoral Program in Medicine: Clinical and Experimental Neurosciences. Neuropsychology (IDIBAPS). She presented her dissertation in July 2017 entitled: "Neuropsychological and genetic factors associated with incipient dementia from Mild Cognitive Impairment. Genotype-phenotype correlation". She is part of the research team of the Center for Biomedical Research Network on Neurodegenerative Diseases (CIBERNED) as well as in national projects (DEGESCO). She has an extensive experience in the investigation of risk factors for conversion to dementia from mild cognitive impairment, with 41 research articles in high-impact international scientific journals. Her h index is 21, with over 1,790 citations of all her publications.
Eli Lilly and Company
Neuroscience
Cynthia Evans, PhD is a clinical research scientist in the Alzheimer’s Disease Development Unit at Eli Lilly and Company. Before coming to Lilly in 2016 she held basic and clinical neuroscience research positions at Washington University School of Medicine, Rockefeller University, Genentech, and UC Berkeley where she earned her PhD. Cynthia also served as Director of the New York Academy of Sciences’ Alzheimer’s Disease and Dementia Initiative and was an active member of the World Health Organization Dementia Working Group. She has spent the majority of her career exploring mechanisms of neurodegeneration and aiming to advance therapies to prevent or slow the progression of Alzheimer’s disease.
UCL Queen Square Institute of Neurology
Clinical and Movement Neurosciences
no photo
Keele University
School of Pharmacy and Bioengineering
Research Associate based at Keele University (United Kingdom). Research interests include exploring the role played by metals in neurodegenerative disorders, particularly the transition metals iron and copper in Alzheimer’s disease. Specialising in utilising multidisciplinary methods for characterising the nanoscale chemical composition of biological specimens, with a focus on the application of advanced synchrotron x-ray techniques. Recent research highlights include: (i) the discovery of metallic elemental nanoparticles in Alzheimer’s disease amyloid plaques using nanofocus x-ray spectromicroscopy [Everett et al., Science Advances. 7, eabf6707 (2021). doi:10.1126/sciadv.abf6707]; (ii) label-free nanoimaging of neuromelanin in the brain by soft x-ray spectromicroscopy [Brooks and Everett et al., Angewandte Chemie. 59, 11984 (2020). doi.org/10.1002/anie.202000239]; (iii) demonstrating the chemical reduction of ferritin iron in the presence of aggregating β-amyloid (1-42) [Everett et al., Scientific Reports. 10, 10332 (2020). doi.org/10.1038/s41598-020-67117-z].
Ludwig Maximilian University Munich
Institute for Stroke and Dementia Research
Dr. Michael Ewers received his PhD in Cognitive Psychology in 2003, following a Fulbright scholarship in 1998. Michael worked as a post-doc at the Ludwig Maximilian University, and subsequently as research scientist at institutions including Trinity College Dublin (Ireland) and University of California at San Francisco (USA). Since 2012 he is Associate Professor at the Ludwig-Maximilian-University Munich. Michael Ewers is head of the neuroimaging facility at the Institute of Stroke and Dementia Research at the University Hospital, LMU and is leading a research group on neuroimaging and biomarker research in Alzheimer’s disease. Michael Ewers’ lab combines functional connectomics, genetics and molecular PET markers to model the spatiotemporal evolution of fibrillar tau and beta-amyloid. The lab has developed connectome-based prediction models for the patient-tailored prediction of tau pathology (Franzmeier et al. Nature Comm 2020, Science Adv 2021). Another major research centers on the understanding of reserve and resilience in Alzheimer’s disease, which lead to the discovery of major hubs that support cognitive resilience in Alzheimer’s disease (Franzmeier et al. Brain, 2018, Ewers et al. Brain 2020). His lab also revealed the protective of a SNP in the longevity gene KLOTHO on the progression of tau pathology in Alzheimer’s (Neitzel et al Nature Comm 2021). Michael Ewers is senior editor of the Alzheimer Association’s journal Alzheimer’s & Dementia, and has published over 130 publications with > 10000 citations, and an H-index of 56 (Google scholar). Dr. Ewers received several awards, most recently the deLeon Senior Researcher Prize 2021 at the Alzheimer’s Association International Conference (AAIC).